Insiders · KLRS

KLRS insider transactions

Kalaris Therapeutics Inc. (KLRS) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.

KLRS insiders

Everyone who has filed a Form 3, 4, 5 or 144 at Kalaris Therapeutics Inc., latest first. Follow anyone to get their next filing.

• Amy O'Leary VandekopVP, Corporate Controller, since July 2026
• Laurie KeatingDirector, since August 2026
• Liisa Ann BaykoChief Financial Officer, since July 2026
• Morana Jovan-EmbiricosDirector-$714K
• Napoleone FerraraDirector, since March 2025
• David HallalDirector-$8.93M
• Srinivas AkkarajuDirector, since March 2025+$6.18M
• Michael DybbsDirector, since March 2025
• Anthony P AdamisDirector, since March 2025
• Leone D PattersonDirector, since April 2025
• Brett R HagenChief Accounting Officer-$728K
• Andrew OxtobyOfficer, Director, since March 2025
• Matthew GallChief Financial Officer, since November 2025
• Matthew FeinsodChief Medical Officer, since March 2025
• Samir Chandrakant PatelDirector, since March 2025
• Samsara BioCapital GP, LLC10% owner, since March 2025
• Vikas SinhaOfficer, Director, 10% owner-$246K
• Edward MillerGeneral Counsel-$297K
• Diana BrainardChief Executive Officer, Director-$676K
• Derek N. AdamsDirector
• Juan VeraDirector-$5.06M
• Shawn TomaselloDirector, since March 2022
• Jeffrey S BornsteinDirector+$67.5K-$832K
• Malcolm BrennerDirector-$7.34M
• Cintia PiccinaOfficer, since June 2023
• Gilead Sciences, Inc.10% owner, since July 2022+$11M
• Ann M. LeenOfficer-$5.39M
• Jeroen B Van BeekOfficer-$6.02M
• Ercem AtillasoyOfficer-$135K
• F2 MG LtdDirector, 10% owner, since July 2022
• ElevateBio, LLCDirector, 10% owner
• Ansbert GadickeDirector, 10% owner
• Agustin MelianOfficer-$3.79M
• John Robert WilsonDirector-$6.27M

Recent Form 3, 4, and 5 filings for KLRS

• 74d
  SEC Form 4 filed by VP, Corporate Controller Vandekop Amy O'Leary

  4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
• 99d
  SEC Form 4 filed by Director Keating Laurie

  4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
• 99d
  SEC Form 3 filed by new insider Keating Laurie

  3 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
• 106d
  New insider Vandekop Amy O'Leary claimed ownership of 948 shares (SEC Form 3)

  3 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
• 113d
  SEC Form 4 filed by Chief Financial Officer Bayko Liisa Ann

  4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
• 113d
  SEC Form 3 filed by new insider Bayko Liisa Ann

  3 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
• 159d
  SEC Form 4 filed by Director Jovan-Embiricos Morana

  4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
• 159d
  SEC Form 4 filed by Director Ferrara Napoleone

  4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
• 159d
  SEC Form 4 filed by Director Hallal David

  4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
• 159d
  SEC Form 4 filed by Director Akkaraju Srinivas

  4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
• 159d
  SEC Form 4 filed by Director Dybbs Michael

  4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
• 159d
  SEC Form 4 filed by Director Adamis Anthony P

  4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
• 159d
  SEC Form 4 filed by Director Patterson Leone D

  4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
• 172d
  Director Akkaraju Srinivas bought $1,179,969 worth of shares (244,300 units at $4.83), disposed of 66,906 shares and acquired 19,408 shares (SEC Form 4)

  4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
• 232d
  SEC Form 4 filed by Hagen Brett R

  4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
• 235d
  SEC Form 4 filed by Oxtoby Andrew

  4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
• 235d
  SEC Form 4 filed by Gall Matthew

  4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
• 235d
  SEC Form 4 filed by Feinsod Matthew

  4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
• 266d
  Director Akkaraju Srinivas bought $5,000,006 worth of shares (479,847 units at $10.42) (SEC Form 4)

  4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
• 323d
  Director Akkaraju Srinivas was granted 1,500,000 shares (SEC Form 4)

  4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
• 372d
  SEC Form 4 filed by Chief Financial Officer Gall Matthew

  4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
• 372d
  SEC Form 3 filed by new insider Gall Matthew

  3 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
• 578d
  SEC Form 4 filed by Director Patel Samir Chandrakant

  4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
• 578d
  SEC Form 4 filed by Director Jovan-Embiricos Morana

  4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
• 578d
  SEC Form 4 filed by Director Akkaraju Srinivas

  4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
• 578d
  SEC Form 4 filed by Chief Accounting Officer Hagen Brett R

  4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
• 578d
  SEC Form 4 filed by Director Ferrara Napoleone

  4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
• 578d
  SEC Form 4 filed by Officer Oxtoby Andrew

  4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
• 578d
  SEC Form 4 filed by Director Adamis Anthony P

  4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
• 578d
  SEC Form 4 filed by Chief Medical Officer Feinsod Matthew

  4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
• 578d
  SEC Form 4 filed by Director Patterson Leone D

  4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
• 578d
  SEC Form 4 filed by Director Hallal David

  4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
• 585d
  SEC Form 3 filed by new insider Patterson Leone D

  3 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)